Gene Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
Entrez Id: 1813
Gene Symbol: DRD2
DRD2
0.400 GeneticVariation group BEFREE The DRD2 A1 allele was present in 73.9% of the obese subjects with comorbid substance use disorder compared to 23.5% in obese subjects without comorbid substance use disorder. 8873216 1996
Entrez Id: 1813
Gene Symbol: DRD2
DRD2
0.400 GeneticVariation group BEFREE The identification of phenotypes of DRD2 genotypes suggests that the observed intronic DRD2 mutations may have functional consequences that predispose individuals to a variety of substance use disorders. 9650634 1998
Entrez Id: 1813
Gene Symbol: DRD2
DRD2
0.400 GeneticVariation group BEFREE Additional data are accruing which also implicate the DRD2 Al and Bl alleles in substance use disorders other than alcoholism. 8512526 1993
Entrez Id: 1813
Gene Symbol: DRD2
DRD2
0.400 GeneticVariation group BEFREE Because the D2 dopamine receptor (DRD2) A1 allele has been associated with alcoholism and other substance use disorders, negative affect, measured by the Beck Depression Inventory (BDI), was determined in four groups of children: boys and girls with the A1+ allele (A1A1 and A1A2 genotypes) and with the A1- allele (A2A2 genotype). 13679114 2003
Entrez Id: 1813
Gene Symbol: DRD2
DRD2
0.400 GeneticVariation group BEFREE A total of 110 adult patients with ASD (n=61) or ADHD (n=49) with or without a lifetime history of SUD participated in a study in which we genotyped polymorphisms in five known candidate genes for (one of) the disorders, i.e. the 5HTTLPR in SLC6A4/5-HTT, rs1800497 (TaqIA C>T) in DRD2, rs7794745 in CNTNAP2, rs1843809 in TPH2, and rs6565113 in CDH13. 20446882 2010
Entrez Id: 1813
Gene Symbol: DRD2
DRD2
0.400 GeneticVariation group BEFREE In the presented study, one of selected polymorphisms of DRD2 gene, revealed to be correlated with substance use disorder (at the limit of statistical significance), which could suggest its impact on dependence endophenotype. 30659563 2018
Entrez Id: 1813
Gene Symbol: DRD2
DRD2
0.400 Biomarker group CTD_human Imaging gene-substance interactions: the effect of the DRD2 TaqIA polymorphism and the dopamine agonist bromocriptine on the brain activation during the anticipation of reward. 16901644 2006
Entrez Id: 1813
Gene Symbol: DRD2
DRD2
0.400 GeneticVariation group BEFREE We hypothesize that dopamine D2 receptor (DRD2) gene Taq1 A2 allele is associated with a subtype of non-SUD schizophrenics and as such may act as a putative protective agent against the development of addiction to alcohol or other drugs of abuse. 24636783 2014
Entrez Id: 1813
Gene Symbol: DRD2
DRD2
0.400 GeneticVariation group BEFREE However, a meta-analysis of a large number of Caucasian alcoholics (both more severe and less severe) and controls (both assessed and unassessed for substance use disorders) revealed a significantly higher frequency (p < 10(-6)) and prevalence (p < 10(-8)) of the DRD2 A1 allele in the alcoholics. 11256581 2000
Entrez Id: 1813
Gene Symbol: DRD2
DRD2
0.400 Biomarker group BEFREE The DRD2 gene has also been found to be involved in other substance use disorders including cocaine, nicotine and opioid dependence, and obesity. 10881203 2000
Entrez Id: 1813
Gene Symbol: DRD2
DRD2
0.400 Biomarker group BEFREE This is the fourth sample that independently associated the DRD2-DRD4 interaction with SUD itself or related disorders. 30367264 2019
Entrez Id: 1813
Gene Symbol: DRD2
DRD2
0.400 GeneticVariation group BEFREE Analysis of the available data suggests that the DRD2 variants represent one of the most prominent single-gene determinants of susceptibility to severe alcoholism and other substance use disorders. 8974314 1994
Entrez Id: 1813
Gene Symbol: DRD2
DRD2
0.400 GeneticVariation group BEFREE Furthermore, sib pair analysis incorporating information across all three sib pair categories: concordant affected, discordant and concordant unaffected revealed no effect of DRD2 genotype or haplotype on alcoholism or substance use disorder. 9259374 1997
Entrez Id: 1813
Gene Symbol: DRD2
DRD2
0.400 GeneticVariation group BEFREE If music causes a powerful activation in spite of the DRD2 A1 allele due to a strong DA neuronal release which subsequently impinges on existing D2 receptors, then it is reasonable to assume that music is a strong indirect D2 agonist (by virtue of DA neuronal release in the NAc) and may have important therapeutic applicability in Reward Deficiency Syndrome (RDS) related behaviors including Substance Use Disorder (SUD).Ross et al. 19914781 2010
Entrez Id: 1813
Gene Symbol: DRD2
DRD2
0.400 GeneticVariation group BEFREE Genetic studies support the Al allele of the D2 dopamine receptor gene (DRD2) as a risk marker for alcoholism and substance use disorders. 16102380 2005
Entrez Id: 6532
Gene Symbol: SLC6A4
SLC6A4
0.390 GeneticVariation group BEFREE SUD and NSUD disorders were diagnosed according to the fourth edition of the Diagnostic and Statistical Manual of Mental Health Disorders criteria using the Psychiatric Research Interview for Substance and Mental Disorders.Incidence Rates (IR) are presented.The 5-HTTLPR polymorphism was analyzed.Hardy-Weinberg equilibrium was studied. 19878141 2010
Entrez Id: 6532
Gene Symbol: SLC6A4
SLC6A4
0.390 GeneticVariation group BEFREE Childhood adversities and the 5-HTTLPR polymorphism are involved in the aetiology of substance use disorders though findings exploring the existence of a gene-environment interaction were inconclusive. 31488488 2019
Entrez Id: 6532
Gene Symbol: SLC6A4
SLC6A4
0.390 GeneticVariation group BEFREE Serotonin transporter promoter polymorphism (5-HTTLPR) genotype was previously found associated with substance use disorders, particularly in the subjects with comorbid antisocial behavior, and with temperament and personality traits at risk for substance abuse. 15666036 2005
Entrez Id: 6532
Gene Symbol: SLC6A4
SLC6A4
0.390 GeneticVariation group BEFREE Using the genotype data of 55 studies (7999 cases, 8264 controls, and 676 families or parent-offspring trios) published in the past 15 years, we have conducted comprehensive meta-analyses to examine the associations of the 5-HTTLPR and STin2 polymorphisms with substance use disorder. 23518607 2013
Entrez Id: 6532
Gene Symbol: SLC6A4
SLC6A4
0.390 Biomarker group BEFREE We found three candidate genes associated with both BD and TUD (COMT, SLC6A3, and SLC6A4) and commonality analysis suggests that these genes interact in predisposing psychiatric and substance use disorders. 20102619 2010
Entrez Id: 6532
Gene Symbol: SLC6A4
SLC6A4
0.390 GeneticVariation group BEFREE This is the first study to show that both familial risk of SUD and 5-HTTLPR variation impact performance on the IGT. 24988263 2014
Entrez Id: 6532
Gene Symbol: SLC6A4
SLC6A4
0.390 GeneticVariation group BEFREE A total of 110 adult patients with ASD (n=61) or ADHD (n=49) with or without a lifetime history of SUD participated in a study in which we genotyped polymorphisms in five known candidate genes for (one of) the disorders, i.e. the 5HTTLPR in SLC6A4/5-HTT, rs1800497 (TaqIA C>T) in DRD2, rs7794745 in CNTNAP2, rs1843809 in TPH2, and rs6565113 in CDH13. 20446882 2010
Entrez Id: 6532
Gene Symbol: SLC6A4
SLC6A4
0.390 GeneticVariation group BEFREE Our data suggest that a decreased expression of the gene encoding the 5-HTT transporter, due to "S" promoter polymorphism, may be associated with an increased risk for substance use disorders, particularly in the subjects with more consistent aggressiveness and impulsiveness. 15048645 2004
Entrez Id: 6532
Gene Symbol: SLC6A4
SLC6A4
0.390 GeneticVariation group BEFREE On the whole, our preliminary data suggest that the association between 5-HT transporter polymorphism and psycho-stimulant use may be mediated by mother-child relationship and parental attachment perception, both being environmental and genetic factors involved in the proneness to substance use disorders, particularly in aggressive-antisocial individuals. 16972224 2007
Entrez Id: 6532
Gene Symbol: SLC6A4
SLC6A4
0.390 Biomarker group CTD_human Serotonin transporter promoter region polymorphisms do not influence treatment response to escitalopram in patients with major depression. 19272758 2009